FLSM
DSGN icon

Frazier Life Sciences Management’s Design Therapeutics DSGN Stock Holding History

Frazier Life Sciences Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2M Buy
+1,809,854
New +$22.6M 0.57% 28
2026
Q1 		– Sell
-521,000
Closed -$4.89M – 40
2025
Q4 		$4.89M Sell
521,000
-1,432,547
-73% -$11.2M 0.13% 38
2025
Q3 		$14.7M Hold
1,953,547
– – 0.44% 34
2025
Q2 		$6.58M Hold
1,953,547
– – 0.26% 42
2025
Q1 		$7.54M Hold
1,953,547
– – 0.34% 35
2024
Q4 		$12.1M Buy
1,953,547
+61,000
+3% +$353K 0.5% 33
2024
Q3 		$10.2M Buy
1,892,547
+697,368
+58% +$3.28M 0.41% 37
2024
Q2 		$4M Buy
+1,195,179
New +$4.66M 0.19% 46

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

Frazier Life Sciences Management's DSGN Position: Q2 2026 in Review

Frazier Life Sciences Management opened a new position in Design Therapeutics (DSGN) in Q2 2026: 1,809,854 shares worth $26.2M. The stake represents 0.57% of the portfolio and ranks #28 among its holdings. This is a return to the name: Frazier Life Sciences Management previously reported a position in DSGN as recently as Q4 2025.

Frazier Life Sciences Management first reported a position in DSGN in Q2 2024 and has held it in 8 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Frazier Life Sciences Management held 1,809,854 shares of Design Therapeutics worth $26.2M as of Q2 2026.
  • Design Therapeutics was a new Frazier Life Sciences Management position in Q2 2026.
  • Design Therapeutics made up 0.57% of Frazier Life Sciences Management's portfolio in Q2 2026, its #28 holding.
  • Frazier Life Sciences Management first reported a position in Design Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.